Navigation Links
Enigma Diagnostics Announces a Signed Term Sheet for Patent Licenses with Roche Molecular Systems, Inc.
Date:12/16/2008

PORTON DOWN, England and SAN FRANCISCO, Dec. 16 /PRNewswire/ -- Enigma Diagnostics Limited, the decentralized and point-of-care molecular diagnostics company, announced today that it has signed a term sheet for two patent license agreements with Roche Molecular Systems, Inc. (RMS).

The licenses will provide Enigma full access under patents owned or licensed by RMS and its affiliates to practice HybProbe real-time PCR chemistry and will allow Enigma to commercialize HybProbe diagnostic PCR tests for human and veterinary in vitro diagnostics on a worldwide basis, complementing Enigma's existing license under patents owned by Celera Diagnostics for real-time PCR thermal cyclers.

Enigma is currently developing a series of multiplexed, HybProbe assays for infectious diseases including chlamydia, influenza and MRSA. These tests will be combined with Enigma's revolutionary and fully automated real-time PCR system, the Enigma ML, to enable one-step molecular testing at point of care.

Financial terms were not disclosed.

    UK Contact:
    Enigma Diagnostics
    Deborah Cordingley
    deborah.cordingley@enigmadiagnostics.com
    +44 1980 590131

    US Contact:
    Richard Lewis Communications, Inc.
    212-827-0020
    Megan Dubrowski - Media
    mdubrowski@rlcinc.com
    Cecelia Heer - Investors
    cheer@rlcinc.com

About Enigma Diagnostics Limited

Enigma Diagnostics Limited is a private UK-based company specializing in developing the next generation of rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings.

Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for field-based, decentralized and point-of-care tests providing results from a raw sample in less than 45 minutes.

The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high-value Applied Markets. Enigma's commercialization strategy is to maximize revenues from a continuous flow of market leading rapid diagnostic point-of care and in-field instrument and assay platforms, derived from its broad Intellectual Property portfolio of issued and filed patents. Enigma will partner with market leaders where global penetration of markets is required and where appropriate will build an in-house sales and marketing capability to direct distribution of its products.

Enigma has an exclusive license from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded research and has licences from Applied Biosystems and Celera Licences for the commercialization of real-time PCR instruments. Enigma's R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.

For more information visit www.enigmadiagnostics.com


'/>"/>
SOURCE Enigma Diagnostics Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Quest Diagnostics to Speak at the Bear Stearns Healthcare Conference
2. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
3. Hypertension Diagnostics Announces Fiscal Year 2007 Results
4. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
5. Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger
6. Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software
7. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
8. HealthShares(TM) Announces Changes to the HealthShares(TM) Diagnostics and Composite Indexes
9. Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations
10. Quest Diagnostics Reports Third Quarter Results
11. ICx Technologies and Siemens Medical Solutions Diagnostics Enter In Vitro Diagnostics Development and License Option Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... Medical Center joined the Peoples Health network on Dec. 1, 2016. Peoples ... , “JenCare Senior Medical Center is an exciting addition to our provider network, ...
(Date:1/17/2017)... ... January 17, 2017 , ... Wettstein Agencies, a ... and business professionals throughout central Colorado, is joining local nonprofit Aurora Warms The ... Warms The Night organization is committed to breaking the cycle of homelessness and ...
(Date:1/17/2017)... ... January 17, 2017 , ... The Sharie Withers ... has announced the latest beneficiary of their thriving community involvement program. The current ... to fulfilling the dreams of terminally ill patients. Donations to this worthy cause ...
(Date:1/16/2017)... ... January 17, 2017 , ... To ... internationally recognized leader in the fast-casual category, announces a hearty and wholesome Winter ... Egg Breakfast Sandwich, Turkey Mash-Up Sandwich, Cranberry Crunch & Honey Parfait, Slow Cooked ...
(Date:1/16/2017)... ... January 16, 2017 , ... With the Grand Opening Event planned for ... use by sports teams and the general public. Built in five months by Centerpoint, ... be converted into basketball or pickleball courts. The space is also suitable for indoor ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan 17, 2017 Research and ... Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), ... - Global Forecast to 2021" report to their offering. ... The global active ... 2021 from USD 157.95 Billion in 2016, growing at a CAGR ...
(Date:1/17/2017)... 17, 2017 Immune Pharmaceuticals (NASDAQ: ... today that it will hold a Satellite Symposium on February ... (ISAL) XVI in Munich, Germany . ... Efficacy of Immunotherapy for the maintenance of remission in ... 20 th , 2017 from 12:45 – 13:45 CET ...
(Date:1/17/2017)... PARSIPPANY, N.J. , Jan. 17, 2017 Interpace ... that provides clinically useful molecular diagnostic tests and pathology ... it has received a letter dated January 13, 2017 ... it has regained compliance with the requirement of the ... price of $1.00 per share. The letter ...
Breaking Medicine Technology: